Kezar Life Sciences Jumps 77% After Topline Results of Lupus Treatment Trials
(Kezar) Shares of Kezar Life Sciences rose more than 77% on Tuesday after reporting positive topline results for its novel selective immunoproteasome inhibitor. The company said that a Phase 2…